C4 Therapeutics Inc（CCCC）のニュースとイベントCCCCC4 Therapeutics Inc

C4 Therapeutics Presents New Data on Cemsidomide Clinical Trial

C4 Therapeutics presented new biomarker data from its Phase 1 clinical trial of cemsidomide in combination with dexamethasone in patients with relapsed/refractory multiple myeloma, RRMM, in a poster presentation at the 23rd IMS Annual Meeting. In addition, the poster included preliminary biomarker data from the first two patients in the ongoing Phase 1b trial of cemsidomide in combination with elranatamab. Key highlights: Immunomodulatory Effects of Cemsidomide with Dexamethasone from Phase 1 Trial Demonstrated Robust T-cell Activation; Biomarker Data from First Two Patients in Phase 1b Trial of Cemsidomide with Elranatamab Reinforce Cemsidomide's Ability to Drive T-cell Expansion and Activation, and Prevent T-cell Exhaustion When Combined with Immune-based Therapies; First Cemsidomide Dose Level in Phase 1b Trial with Elranatamab Declared Safe by Safety Data Review Committee; Advancing Trial to Dose Expansion and Escalation Cohorts with Data from All Cohorts Evaluated Expected in Mid-2027

C4 Therapeutics Q2 Revenue $6.64M, Exceeds Expectations

Reports Q2 revenue $6.64M, consensus $4M. "The first half of 2026 was a period of execution for cemsidomide, our next-generation IKZF1/3 degrader, and our clinical development plan. At the EHA Congress in June, we presented clinical data that further supported cemsidomide's differentiated and potential best-in-class profile for the treatment of relapsed refractory multiple myeloma. In addition, insights from our June KOL webinar underscored the importance of IKZF1/3 degradation as a foundational mechanism in multiple myeloma and highlighted the potential for next-generation IKZF1/3 degraders to become a cornerstone therapy across the disease continuum," said Andrew Hirsch, president and chief executive officer of C4 Therapeutics. "As we enter the second half of the year, we remain focused on advancing the Phase 2 MOMENTUM trial, the Phase 1b combination trial with elranatamab and start-up activities for our additional Phase 1b combination trial with approved standard-of-care multiple myeloma therapies. Together, these studies are expected to generate clinical milestones in 2027 and beyond and will support our vision of establishing cemsidomide as a potential backbone therapy for combination regimens in multiple myeloma."

C4 Therapeutics Presents Cemsidomide Data at EHA 2026 Congress

C4 Therapeutics will present further analysis from its fully enrolled Phase 1 trial of cemsidomide, a next-generation oral IKZF1/3 degrader, in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma in a poster presentation at the European Hematology Association, or EHA, 2026 Congress on Friday, June 12. The poster presentation includes data on 73 patients with a data cutoff of February 27. Patients were heavily pretreated, receiving a median of seven prior lines of therapy. Fifty-five patients received prior BCMA therapy, and 55 patients received prior CAR-T or T-cell engager therapy. At the RP2D and maximum tolerated dose cemsidomide achieved a 53% overall response rate. At the 75 microgram dose level, cemsidomide achieved a 40% ORR. Across all doses evaluated, cemsidomide achieved a 36% ORR. Responses deepened over time across the cemsidomide 75 microgram and 100 microgram dose levels: at 75 microgram, one patient whose best response was previously a partial response deepened to a very good partial response. At 100 microgram, several patients achieved a deeper response: one patient whose best response was previously a PR deepened to a stringent complete response; one patient whose best response was previously a PR deepened to a VGPR; minimal residual disease negativity was achieved in two patients who achieved a sCR and complete response at 100 microgram. ORR was consistent across key subgroups. Patients experienced a median duration of response of 7.9 months. Seven patients remain on treatment currently. Cemsidomide in combination with dexamethasone was generally well tolerated. Incidences of on-target neutropenia remained manageable; 42 patients experienced Grade 3/4 neutropenia. All treatment emergent adverse events were manageable with no discontinuations deemed related to cemsidomide and minimal dose reductions.